Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.
Thomas M CaparrottaJack B TempletonThomas A ClaySarah H WildRebecca M ReynoldsDavid J WebbHelen M ColhounPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
In T2D, GLP1RAs appear safe from the CV perspective and (for liraglutide) may have associated benefit in primary as well as secondary CVD prevention. For non-CV safety, GLP1RA exposure was not associated with an increased risk of AP, PC, BC or hypoglycaemia; the other outcomes had too few studies to draw firm conclusions and should be explored further.